Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 18/20 | 0.67 |
| ▸ | OXTR | P30559 | 11/20 | 0.67 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.46 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660513 | 1.00 | AVPR2 (0.67) | AVPR2OXTRAVPR1AAVPR1BCHRM2 | |
| Trifluoroacetic Acid SCHEMBL6202890 | 0.95 | AVPR2 (0.62) | AVPR2OXTRAVPR1AAVPR1BCHRM2 | |
| SCHEMBL5435288 | 0.87 | AVPR2 (0.88) | AVPR2OXTRAVPR1ACHRM2CHRM4 | |
| SCHEMBL6202894 | 0.86 | AVPR2 (0.53) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL6366104 | 0.80 | AVPR2 (0.51) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL38963 | 0.79 | AVPR2 (0.47) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL1662737 | 0.76 | AVPR2 (0.73) | AVPR2OXTRAVPR1ACHRM2CHRM4 | |
| SCHEMBL6202295 | 0.75 | AVPR1A (0.46) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL6202233 | 0.74 | AVPR2 (0.67) | AVPR2OXTRAVPR1A | |
| SCHEMBL6202773 | 0.74 | AVPR1A (0.55) | AVPR2OXTRAVPR1AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | WYETH (US) | 2007-05-24 | — | — | US | claimed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | claimed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | claimed |
| US-20160058830-A1 | Therapy and Prevention of Problem Drinking | THE UNIVERSITY OF SYDNEY (AU) | 2016-03-03 | — | — | US | disclosed |
| US-9125862-B2 | Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9119805-B2 | Therapy and prevention of problem drinking | THE UNIVERSITY OF SYDNEY (AU) | 2015-09-01 | — | — | US | disclosed |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8853158-B2 | Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20130102528-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | CHU DE TOULOUSE (FR) | 2013-04-25 | — | — | US | disclosed |
| US-20120270785-A1 | Therapy and Prevention of Problem Drinking | THE UNIVERSITY OF SYDNEY (AU) | 2012-10-25 | — | — | US | disclosed |
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | WYETH (US) | 2007-05-24 | — | — | US | disclosed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | OXTR, AVPR1A, PRLHR | AVPR2 8/4885OXTR 1/4885AVPR1A 2/4885 |
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | AVPR2 10/4885OXTR 1/4885AVPR1A 7/4885 |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | AVPR2 12/4885OXTR 1/4885AVPR1A 10/4885 |
| US-20160058830-A1 | Therapy and Prevention of Problem Drinking | OXTR, AVPR1B, AVPR1A | AVPR2 4/4885OXTR 1/4885AVPR1A 3/4885 |
| US-20120270785-A1 | Therapy and Prevention of Problem Drinking | OXTR, AVPR1B, AVPR1A | AVPR2 4/4885OXTR 1/4885AVPR1A 3/4885 |
| US-20130102528-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | AVPR2 12/4885OXTR 1/4885AVPR1A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.